Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;118(12):2106-2108.
doi: 10.14309/ajg.0000000000002463. Epub 2023 Aug 10.

Practical Use of Fecal Microbiota Spores, Live BRPK for the Prevention of Recurrent Clostridioides difficile Infection

Jessica R Allegretti  1 , Sahil Khanna  2 , Paul Feuerstadt  3
Affiliations

Practical Use of Fecal Microbiota Spores, Live BRPK for the Prevention of Recurrent Clostridioides difficile Infection

Jessica R Allegretti et al. Am J Gastroenterol. .
No abstract available

PubMed Disclaimer

References

    1. Feuerstadt P, Allegretti JR, Khanna S. Practical use of RBX2660 for the prevention of recurrent Clostridioides difficile infection. Am J Gastroenterol 2023;118:1303–6.
    1. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435–8.
    1. Khanna S, Sims M, Louie TJ, et al. SER-109: An oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics (Basel) 2022;11:1234.
    1. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med 2022;386:220–9.
    1. Cohen SH, Louie TJ, Sims M, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA 2022;328:2062–4.

LinkOut - more resources